Arvinas (NASDAQ:ARVN) Upgraded to Strong-Buy at Zacks Research

Arvinas (NASDAQ:ARVN) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

ARVN has been the subject of several other reports. BTIG Research reiterated a “buy” rating and set a $18.00 target price on shares of Arvinas in a research report on Tuesday. Barclays upped their price target on shares of Arvinas from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Weiss Ratings downgraded shares of Arvinas from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. Wedbush lifted their price objective on shares of Arvinas from $11.00 to $12.00 and gave the company a “neutral” rating in a report on Wednesday. Finally, Stephens reissued an “overweight” rating and issued a $18.00 price objective on shares of Arvinas in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Arvinas currently has an average rating of “Hold” and a consensus price target of $14.90.

Arvinas Stock Performance

Shares of ARVN stock opened at $8.68 on Wednesday. Arvinas has a 52-week low of $6.05 and a 52-week high of $14.51. The firm has a market capitalization of $560.03 million, a P/E ratio of 86.81 and a beta of 1.71. The stock has a 50 day moving average price of $8.06 and a 200 day moving average price of $10.25.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $2.95. The company had revenue of $249.70 million during the quarter, compared to analysts’ expectations of $60.71 million. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.Arvinas’s revenue was up 1014.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.84) EPS. As a group, sell-side analysts forecast that Arvinas will post -2.39 EPS for the current year.

Insiders Place Their Bets

In other Arvinas news, CFO Andrew Saik sold 11,139 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $110,721.66. Following the completion of the sale, the chief financial officer directly owned 193,128 shares in the company, valued at approximately $1,919,692.32. This represents a 5.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Randy Teel sold 9,657 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $95,990.58. Following the transaction, the chief executive officer directly owned 287,218 shares in the company, valued at $2,854,946.92. The trade was a 3.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 41,728 shares of company stock worth $402,649 in the last ninety days. 7.30% of the stock is owned by company insiders.

Institutional Trading of Arvinas

Hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC grew its holdings in Arvinas by 50.0% during the 4th quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock worth $21,348,000 after acquiring an additional 600,000 shares in the last quarter. TCG Crossover Management LLC bought a new stake in shares of Arvinas in the 3rd quarter valued at about $13,780,000. Qube Research & Technologies Ltd raised its holdings in shares of Arvinas by 154.8% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock valued at $12,668,000 after purchasing an additional 903,337 shares in the last quarter. Millennium Management LLC lifted its position in shares of Arvinas by 208.4% in the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after purchasing an additional 885,483 shares during the period. Finally, Balyasny Asset Management L.P. lifted its position in shares of Arvinas by 469.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 1,207,267 shares of the company’s stock worth $10,286,000 after purchasing an additional 995,125 shares during the period. 95.19% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Arvinas received a Zacks Rank #1 (Strong Buy), reflecting improved expectations for its earnings outlook and potentially supporting near-term buying interest. Arvinas Upgraded to Strong Buy
• Positive Sentiment: HC Wainwright materially raised its FY2026 EPS forecast to a loss of $0.67 from a loss of $3.98, while also improving estimates for FY2027 through FY2030. Its FY2030 forecast moved into profitability at $0.07 per share, suggesting better long-term operating prospects. Arvinas Analyst Estimates
• Positive Sentiment: BTIG Research assigned Arvinas a “Buy” rating, adding to the bullish analyst support. Arvinas Earns Buy Rating from BTIG
• Positive Sentiment: Arvinas’ latest quarterly results substantially exceeded expectations, with $249.7 million in revenue versus a $60.7 million consensus estimate and EPS of $2.58 versus an expected loss. Revenue increased more than tenfold year over year, providing a strong fundamental backdrop. Arvinas Trading Higher on Strong Earnings
• Neutral Sentiment: HC Wainwright lowered its Q3 and Q4 2026 EPS forecasts to losses of $1.20 and $1.19, respectively, but raised most full-year estimates. The mixed revisions indicate near-term profitability remains pressured even as the longer-term outlook improves.
• Negative Sentiment: Wells Fargo downgraded Arvinas to “Equal Weight,” signaling reduced conviction in additional upside and contributing to selling pressure. Arvinas Rating Lowered to Equal Weight
• Negative Sentiment: Shares fell sharply following an analyst downgrade, highlighting the stock’s sensitivity to changes in Wall Street sentiment. Arvinas Shares Down on Analyst Downgrade

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.